Literature DB >> 29766302

Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer.

Filippo Scopelliti1, Antonio Pea2, Rita Conigliaro3, Giovanni Butturini4, Isabella Frigerio4, Paolo Regi4, Alessandro Giardino4, Helga Bertani3, Marina Paini5, Paolo Pederzoli4, Roberto Girelli4.   

Abstract

BACKGROUND AND AIMS: Radiofrequency ablation (RFA) is a well-recognized local ablative technique applied in the treatment of different solid tumors. Intraoperative RFA has been used for non-metastatic unresectable pancreatic ductal adenocarcinoma (PDAC), showing increased overall survival in retrospective studies. A novel RFA probe has recently been developed, allowing RFA under endoscopic ultrasound (EUS) guidance. Aim of the present study was to assess the feasibility and safety of EUS-guided RFA for unresectable PDACs.
METHODS: Patients with unresectable non-metastatic PDAC were included in the study following neoadjuvant chemotherapy. EUS-guided RFA was performed using a novel monopolar 18-gauge electrode with a sharp conical 1 cm tip for energy delivery. Pre- and post-procedural clinical and radiological data were prospectively collected.
RESULTS: Ten consecutive patients with unresectable PDAC were enrolled. The procedure was successful in all cases and no major adverse events were observed. A delineated hypodense ablated area within the tumor was observed at the 30-day CT scan in all cases.
CONCLUSIONS: EUS-guided RFA is a feasible and safe minimally invasive procedure for patients with unresectable PDAC. Further studies are warranted to demonstrate the impact of EUS-guided RFA on disease progression and overall survival.

Entities:  

Keywords:  Endoscopic ultrasound; Pancreatic ductal adenocarcinoma; Radiofrequency ablation; Unresectable pancreatic cancer

Mesh:

Year:  2018        PMID: 29766302     DOI: 10.1007/s00464-018-6217-x

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  21 in total

Review 1.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

2.  Triple approach strategy for patients with locally advanced pancreatic carcinoma.

Authors:  Alessandro Giardino; Roberto Girelli; Isabella Frigerio; Paolo Regi; Maurizio Cantore; Auriemma Alessandra; Annita Lusenti; Roberto Salvia; Claudio Bassi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2012-12-06       Impact factor: 3.647

3.  Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center.

Authors:  Isabella Frigerio; Roberto Girelli; Alessandro Giardino; Paolo Regi; Roberto Salvia; Claudio Bassi
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-08       Impact factor: 7.027

4.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

5.  EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos).

Authors:  Sundeep Lakhtakia; Mohan Ramchandani; Domenico Galasso; Rajesh Gupta; Sushma Venugopal; Rakesh Kalpala; D Nageshwar Reddy
Journal:  Gastrointest Endosc       Date:  2015-09-21       Impact factor: 9.427

6.  Study of apoptosis and heat shock protein (HSP) expression in hepatocytes following radiofrequency ablation (RFA).

Authors:  R Rai; C Richardson; P Flecknell; H Robertson; A Burt; D M Manas
Journal:  J Surg Res       Date:  2005-06-22       Impact factor: 2.192

7.  Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors.

Authors:  Madhava Pai; Nagy Habib; Hakan Senturk; Sundeep Lakhtakia; Nageshwar Reddy; Vito R Cicinnati; Iyad Kaba; Susanne Beckebaum; Panagiotis Drymousis; Michel Kahaleh; William Brugge
Journal:  World J Gastrointest Surg       Date:  2015-04-27

Review 8.  Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer.

Authors:  Patrizia Rovere-Querini; Angelo A Manfredi
Journal:  JOP       Date:  2004-07

Review 9.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

10.  Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer.

Authors:  Tae Jun Song; Dong Wan Seo; Sundeep Lakhtakia; Nageshwar Reddy; Dong Wook Oh; Do Hyun Park; Sang Soo Lee; Sung Koo Lee; Myung-Hwan Kim
Journal:  Gastrointest Endosc       Date:  2015-09-04       Impact factor: 9.427

View more
  18 in total

Review 1.  Endoscopic Management of Pancreatobiliary Malignancies.

Authors:  Dong Wook Lee; Eun Young Kim
Journal:  Dig Dis Sci       Date:  2022-02-16       Impact factor: 3.199

2.  Efficacy and safety of endoscopic ultrasound-guided radiofrequency ablation for management of pancreatic lesions: a systematic review and meta-analysis.

Authors:  Yazan Fahmawi; Ansh Mehta; Haneen Abdalhadi; Lindsey Merritt; Meir Mizrahi
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

3.  EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and oligometastatic disease: an observational prospective multicenter study.

Authors:  Mariana Figueiredo Ferreira; Rodrigo Garces-Duran; Pierre Eisendrath; Jacques Devière; Pierre Deprez; Laurent Monino; Jean-Luc Van Laethem; Ivan Borbath
Journal:  Endosc Int Open       Date:  2022-10-17

4.  Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70.

Authors:  Shanshan Gao; Ning Pu; Hanlin Yin; Junhao Li; Qiangda Chen; Minjie Yang; Wenhui Lou; Yi Chen; Guofeng Zhou; Changyu Li; Guoping Li; Zhiping Yan; Lingxiao Liu; Jun Yu; Xiaolin Wang
Journal:  Ther Adv Med Oncol       Date:  2020-09-10       Impact factor: 8.168

Review 5.  Endoscopic Ultrasound-Guided Management of Pain in Chronic Pancreatitis and Pancreatic Cancer: an Update.

Authors:  Jonathan M Wyse; Anand V Sahai
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 6.  Role of Radiofrequency Ablation in the Management of Unresectable Pancreatic Cancer.

Authors:  Muhammad Nadeem Yousaf; Hamid Ehsan; Ahmad Muneeb; Ahsan Wahab; Muhammad K Sana; Karun Neupane; Fizah S Chaudhary
Journal:  Front Med (Lausanne)       Date:  2021-02-11

Review 7.  Therapeutic EUS: New tools, new devices, new applications.

Authors:  Barbara Braden; Vipin Gupta; Christoph Frank Dietrich
Journal:  Endosc Ultrasound       Date:  2019 Nov-Dec       Impact factor: 5.628

Review 8.  Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy.

Authors:  Florentine E F Timmer; Bart Geboers; Sanne Nieuwenhuizen; Evelien A C Schouten; Madelon Dijkstra; Jan J J de Vries; M Petrousjka van den Tol; Tanja D de Gruijl; Hester J Scheffer; Martijn R Meijerink
Journal:  Curr Oncol Rep       Date:  2021-04-17       Impact factor: 5.075

9.  Possible involvement of HSP70 in pancreatic cancer cell proliferation after heat exposure and impact on RFA postoperative patient prognosis.

Authors:  Hui-Bin Song
Journal:  Biochem Biophys Rep       Date:  2019-10-31

Review 10.  Current role of endoscopic ultrasound in the diagnosis and management of pancreatic cancer.

Authors:  Federico Salom; Frédéric Prat
Journal:  World J Gastrointest Endosc       Date:  2022-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.